Cargando…

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Detalles Bibliográficos
Autores principales:	Mistry, Hema, Nduka, Chidozie, Connock, Martin, Colquitt, Jill, Mantopoulos, Theodoros, Loveman, Emma, Walewska, Renata, Mason, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830393/ https://www.ncbi.nlm.nih.gov/pubmed/30778866 http://dx.doi.org/10.1007/s40273-019-00773-w

Ejemplares similares

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

External validity of rct evidence in cost-effectiveness analyses. A review of recent technology appraisals for nice and proposed methods of adjustment
por: Mantopoulos, Theodoros, et al.
Publicado: (2015)

The cost-effectiveness of osteochondral allograft transplantation in the knee
por: Mistry, Hema, et al.
Publicado: (2019)

Autograft or allograft for reconstruction of anterior cruciate ligament: a health economics perspective
por: Mistry, Hema, et al.
Publicado: (2019)

Allografts in reconstruction of the posterior cruciate ligament: a health economics perspective
por: Waugh, Norman, et al.
Publicado: (2019)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Meniscal allograft transplantation after meniscectomy: clinical effectiveness and cost-effectiveness
por: Waugh, Norman, et al.
Publicado: (2019)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
por: Scott, David A., et al.
Publicado: (2019)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
por: Gribben, John G.
Publicado: (2019)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
por: Woo, Timothy, et al.
Publicado: (2023)

Improving Uptake of Postnatal Checking of Blood Glucose in Women Who Had Gestational Diabetes Mellitus in Universal Healthcare Settings: A Systematic Review
por: Sanderson, Helen, et al.
Publicado: (2018)

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem, et al.
Publicado: (2023)

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia – more than meets the eye
por: Bennett, Rory, et al.
Publicado: (2023)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
por: Rendeiro, André F., et al.
Publicado: (2016)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
por: Loveman, Emma, et al.
Publicado: (2015)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
por: Wierda, William G., et al.
Publicado: (2018)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ren, Shijie, et al.
Publicado: (2018)

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
por: Kaltenthaler, Eva, et al.
Publicado: (2016)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

A Review of Economic Models Submitted to NICE’s Technology Appraisal Programme, for Treatments of T1DM & T2DM
por: Daly, Marie-Josée, et al.
Publicado: (2022)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ou57ppn2iafr13mprv64577cls